Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2023-11-22 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks for Ascletis Pharma Inc., listed on the Stock Exchange of Hong Kong (SEHK). It details numerous repurchases of shares with dates and quantities, confirming compliance with listing rules. The content is a regulatory disclosure about share repurchases, not a financial report or earnings release. It is a formal notification of transactions in the company's own shares (share buybacks). Therefore, the document fits the category of 'Transaction in Own Shares' (POS). The document length and detail confirm it is not a brief announcement but a full disclosure report on share repurchases.
2023-11-22 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued share capital and share buybacks for Ascletis Pharma Inc. It includes detailed tables of repurchase of shares with dates and quantities, confirming it is a report on share repurchase activities. The document references rules from the Stock Exchange of Hong Kong (SEHK) and contains confirmations related to share issues and repurchases. This type of document is a report on transactions in the company's own shares (share buybacks), not a general financial report or announcement of a report. It is not an announcement of a report publication but the actual disclosure of share repurchase transactions. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length (15,000 characters) and detailed transactional data support this classification with high confidence.
2023-11-21 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued share capital and share buybacks for Ascletis Pharma Inc. It includes detailed tables of repurchases of shares with dates and quantities, confirming compliance with listing rules of the Stock Exchange of Hong Kong. The content is focused on reporting share repurchase transactions and changes in issued shares, which aligns with disclosures about transactions in own shares. There is no indication of it being a full financial report, earnings release, or management discussion. The document is substantive and detailed, not a brief announcement or certification. Therefore, the document fits best under the category of 'Transaction in Own Shares' (POS).
2023-11-20 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It contains detailed tables of repurchase transactions, dates, and share quantities. The document references compliance with listing rules of the Stock Exchange of Hong Kong (SEHK) and provides confirmations related to share repurchases. There is no indication of financial statements, earnings data, or management discussion. The content is focused on reporting share repurchase activity, which aligns with the category for company transactions involving its own shares. Therefore, the document fits the 'Transaction in Own Shares' category (POS). The document length and detail confirm it is a report of transactions, not merely an announcement or certification.
2023-11-16 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued share capital and share buybacks for Ascletis Pharma Inc. It includes detailed tables of repurchases of shares with dates, quantities, and prices. The document references compliance with the Main Board Listing Rules and GEM Listing Rules of the Stock Exchange of Hong Kong. The content is focused on reporting share repurchase transactions and changes in issued shares, which aligns with disclosures about transactions in own shares. There is no indication that this is a full financial report, earnings release, or management discussion. The document is not a brief announcement but a detailed regulatory disclosure of share repurchases. Therefore, the most appropriate classification is 'Transaction in Own Shares' (POS). The document length and detail support a high confidence in this classification.
2023-11-15 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and pertains to an equity issuer's changes in issued share capital and share buybacks. It includes detailed tables of repurchases of shares by Ascletis Pharma Inc., with dates and quantities of shares repurchased but not cancelled. The document references compliance with listing rules of the Stock Exchange of Hong Kong (SEHK) and provides confirmations related to share issues and repurchases. The content is focused on reporting share repurchase transactions and changes in issued share capital, not on financial results, management changes, or other report types. This matches the definition of a 'Transaction in Own Shares' filing, which reports the company's buyback or sale of its own shares. The document length is substantial and contains detailed transactional data, confirming it is the report itself, not just an announcement. Therefore, the appropriate classification is 'POS' (Transaction in Own Shares).
2023-11-14 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.